Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Endostar + GDP in Aggressive PTCL
NCT02520219Phase 2Unknown
- Sponsor
- Nanjing Ningqi Pharmaceutical Technology
- Start
- Dec 2014
- Primary completion
- Aug 2015
- Modality
- rProtein (Recombinant Protein), Biologic
- Countries
- 1
01
Overview
A Phase 2 trial of endostar in peripheral T-cell lymphoma (PTCL), sponsored by Nanjing Ningqi Pharmaceutical Technology. Status: unknown.
02
Drugs
endostar
03
Conditions
peripheral T-cell lymphoma (PTCL)
Beyond the preview
Go deeper on NCT02520219.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02520219.